Naproxcinod FDA Approval Status
FDA Approved: No
Generic name: naproxcinod
Company: NicOx S.A.
Treatment for: Duchenne Muscular Dystrophy
Naproxcinod is the first in a new class of anti-inflammatory agents known as CINODs (Cyclooxygenase-Inhibiting Nitric Oxide Donators) in development for the treatment of Duchenne Muscular Dystrophy.
Development timeline for naproxcinod
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.